First report on delineation of differentially expressed genes and pathways in milk somatic cells of mastitic and healthy Murrah buffaloes.

Despite immense contribution of buffaloes as dairy species, limited studies have addressed the bubaline mastitis as compared to cattle. This was the first differential transcriptomic study investigating the alterations induced by clinical mastitis in buffalo milk relative to healthy controls. Comparative gene expression profiling of three biological replicates of each group identified 1014 up-regulated and 999 down-regulated genes in the diseased buffaloes (Fold change > 2, FDR < 0.05). Activation of immune and inflammatory responses were the most enriched GO terms in the mastitic animals, with higher transcript abundance of many genes coding for anti-microbial proteins such as ß-defensins, perforin, granzymes, granulysin, cathelicidins etc. Analysis of the gene regulatory interactions of the up-regulated DEGs identified many hub genes that govern the cellular and macromolecular metabolic processes (E2F4, E2F1, RBL2, FOXM1, IRF1 and MYB). This study contributes to an insightful understanding of molecular mechanisms governing immune response of buffaloes to mastitis.

Clinico-haematological and mineral studies on experimental maduramicin toxicity in chickens.

Clinico-haematological and mineral studies were carried out in experimental chickens given maduramicin medicated feed at 5 and 10 ppm for 21 days. Maduramicin medication in both medicated groups caused growth retardation. Clinical signs namely watery diarrhoea, depression, dullness and ruffled feathers were noticed in chickens from second week of the medication at 10 ppm but this effect was seen from third week in the birds given maduramicin at 5 ppm. Maduramicin medication caused significant reduction in haemoglobin in both the medicated group from day 14 and total erythrocyte count and packed cell volume in 10 ppm group on day 21. There was an increase in MCV in 10 ppm group on day 21 indicating macrocytic anaemia and decrease in mean corpuscular haemoglobin concentration (MCHC) in both the medicated groups indicating hypochromic anaemia. The leucopenia due to lymphopenia was observed in 10 ppm group on day 21. Maduramicin medication caused significant increase in serum Zn in 10 ppm group and decrease in Cu concentration in both the medicated groups from day 14. It is concluded that maduramicin caused toxic effects from day 14 in both the medicated groups.